Mildronate is a registered logo of the Grindex. Its active ingredient is meldonium. Meldonium ingredients a limited-market pharmacological, and is an ‘anti-ischemic’ drug, which is used to treat inadequate blood flow to the organs, specifically the heart. Mildronatedihydrate is an inhibitor of biosynthesis of L-carnitine using gamma-butyrobetaine (GBB) hydroxylase and as a reasonable inhibitor of renal carnitine reabsorption. Its creation has a high technology barrier thus it is a technology severe industry. It has three existence forms, which include mildronate dihydrate injection, mildronate dihydrate capsule, and mildronate dihydrate tablets.
According to the study, “World Mildronate Dihydrate Market Research Report 2024(covering USA, EU, China, South East Asia, Japan and etc)” the key companies operating in the world mildronate dihydrate market is Grindeks.
It is mainly used to treat patients with heart conditions which affect the body’s ability to provide oxygen in the body. It helps to protect against tissue damage from angina attacks, disorders of brain circulation andchronic heart failure. It is clinically used in the treatment of heart failure, arrhythmia, myocardial infarction, atherosclerosis, and diabetes.
Its key mechanism is based on carnitine biosynthesis inhibition proposed to prevent the growth of cytotoxic intermediate products of fatty acid beta-oxidation in ischemic tissues and to block this vastly oxygen-consuming process.Carnitine/organic cation transporter type 2 (OCTN2) and L-Carnitine biosynthesis enzyme γ-butyrobetaine hydroxylase are the main known drug targets of meldonium. Some of the side-effects are included headache, dizziness, nervousness, sleeplessness, a fall in blood pressure, allergic symptoms, and tachycardia.
Based on the form type, the mildronate dihydrate market is segmented into injection, capsule, and tablet. The capsule contains 500mg active ingredient. Based on raw material, the market is segmented into unsymmetrical dimethylhydrazine UDMH,tert-Butyl acrylate TBA, and ethanol, etc. Based on application, market is segmented into cardiovascular disease(treatment of chronic heart ischemic disease, chronic heart failure, stable angina pectoris, functional disorders of heart & vessels, heart infarction, cardiomyopathy), pulmonology(bronchial asthma and obstructive bronchitis), narcology(abstinence syndrome in chronic alcoholism), neurology(acute & chronic ischemic brain circulation disorders, physical &emotional overload, decreased work capabilities, the recovery period after various diseases), ophthalmology(hemophthalm& retina hemorrhages of different etiology, diabetic& hypertonic retinopathies, thrombosis of central vein & its branches in retina,) and others (immune system modulation, treating wye trauma, & stomach ulcers and treating infection of lungs & upper respiratory tract).
In addition, based on end-use, the market is segmented into hospitals &clinics, academic institutes, and research institutions. The mildronate dihydrate market is driven by a rise in cardiovascular disease, followed by increase inpatient population, a rise in awareness of the patient population and an increase in technological advancements. However, the price of the upstream product and lack of funding for research & development (R&D) may impact the market. Moreover, the surge in disposable income is a key opportunity for market.
Based on geography, the USA country holds a major share, followed by the EU mildronate dihydrate market owing to the presence of highly skilled medical professionals and better infrastructure & technological edge in the country. China and Japan countries are expected to witness higher growth rate due to a rise in the aged population and an increase in cardiovascular disease over the forecast period.
Global Mildronate Dihydrate Market:
Product Segment Analysis
Capsule
Injection
Tablet
Global Mildronate Dihydrate Market:
Application Segment Analysis
Patients with cardiovascular disease
Global Mildronate Dihydrate Market:
Regional Segment Analysis
USA
Europe
Japan
China
India
Southeast Asia
The players mentioned in our report
Grindeks
To Know More, Click On The Link Below:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
